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ABSTRACT Innate immune activation is essential to mount an effective antiviral
response and to prime adaptive immunity. Although a crucial role of CD169
cells during vesicular stomatitis virus (VSV) infections is increasingly recognized,
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factors regulating CD169 cells during viral infections remain unclear. Here, we
show that tumor necrosis factor is produced by CD11b Ly6C Ly6G cells fol-
lowing infection with VSV. The absence of TNF or TNF receptor 1 (TNFR1) re-
sulted in reduced numbers of CD169 cells and in reduced type I interferon
(IFN-I) production during VSV infection, with a severe disease outcome. Speciﬁ-
cally, TNF triggered RelA translocation into the nuclei of CD169 cells; this trans-
location was inhibited when the paracaspase MALT-1 was absent. Consequently,
MALT1 deﬁciency resulted in reduced VSV replication, defective innate immune
activation, and development of severe disease. These ﬁndings indicate that TNF
mediates the maintenance of CD169 cells and innate and adaptive immune ac-
tivation during VSV infection.
IMPORTANCE Over the last decade, strategically placed CD169 metallophilic mac-
rophages in the marginal zone of the murine spleen and lymph nodes (LN) have
been shown to play a very important role in host defense against viral pathogens.
CD169 macrophages have been shown to activate innate and adaptive immunity
via “enforced virus replication,” a controlled ampliﬁcation of virus particles. However,
the factors regulating the CD169 macrophages remain to be studied. In this paper,
we show that after vesicular stomatitis virus infection, phagocytes produce tumor
necrosis factor (TNF), which signals via TNFR1, and promote enforced virus replica-
tion in CD169 macrophages. Consequently, lack of TNF or TNFR1 resulted in defec-
tive immune activation and VSV clearance.
KEYWORDS TNF, MALT1, innate immunity, interferon, NF-B, innate immunity,
interferons, tumor necrosis factor
Innate immune activation is crucial for inducing antiviral immunity through cytokineproduction and adaptive immune priming (1). Splenic marginal-zone macrophages
and metallophilic marginal-zone macrophages play an important role in eliminating
blood-borne bacteria, parasites, and viral pathogens (2, 3). Metallophilic macrophages
were originally described when rat splenic marginal-zone macrophages were stained
by iron and silver impregnation (4). These metallophilic macrophages express the
lectin-like hemagglutinin CD169, which was identiﬁed using a monoclonal antibody,
MOMA-1 (5–7). CD169 macrophages are increasingly recognized to play a pivotal role
in host defense (8). CD169macrophages (referred to here as CD169 cells), speciﬁcally
allow early viral replication to promote innate immune recognition and antigen pre-
sentation (9). The absence of CD169 cells results in reduced type I interferon (IFN-I)
production, reduced B-cell activation, and development of severe disease during viral
infection (10, 11). B-cell-derived lymphotoxin alpha (Lt) and lymphotoxin beta (Lt)
drive the maintenance of CD169 cells in spleen and lymph node tissue (10, 12, 13).
Consequently, B-cell-deﬁcient mice exhibit fewer CD169 cells and limited immune
activation, including the production of IFN-I (13, 14). However, the factors promoting
survival and the presence of CD169 cells after viral infection have not yet been
sufﬁciently studied.
IFN-I triggers strong inhibitory effects on viral replication and is crucial for prevent-
ing severe infections with the vesicular stomatitis virus (VSV) model system (1, 15). This
system can be used as a laboratory system for immune recognition during viral
infection, as a vaccine vector system, as a tool for viral transduction, and as an oncolytic
virus (16, 17). Clearance of VSV depends heavily on IFN-I and the presence of neutral-
izing antibodies (15, 18). VSV has been used as a murine model of viral infections to
study the innate immune response and virus replication in secondary lymphoid organs
and the central nervous system (CNS) (19–21). Pathology in VSV infection is seen
particularly during infection of the CNS; this pathology includes paralysis and death
after infection with VSV (22). Accordingly, mice deﬁcient in IFN-/ receptor (IFNAR)
signaling exhibit paralysis and the presence of VSV in the CNS (15). Consistently, IFN-I
can inhibit VSV replication in neurons, and defects in IFN-stimulated genes (ISGs) in the
CNS tissue trigger pathology during VSV infection (23, 24). During infection with low
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doses of VSV, replication of VSV in CD169 cells in the spleen and lymph node tissue
is important for inducing protective immunity and preventing CNS infection (9, 10). The
VSV backbone is also used during vaccination to induce protective immunity against
viruses such as Ebola virus (25).
The role of tumor necrosis factor (TNF) in marginal-zone development and marginal-
zone function is controversial. Although reports show that marginal-zone development
is impaired and fewer marginal-zone macrophages are present in TNF-deﬁcient and
p55-TNFR (tumor necrosis factor receptor 1 [TNFR1])-deﬁcient mice (26), other reports
suggest that TNF triggers marginal-zone macrophage depletion after infection (27, 28).
It has also been shown that TNFR1-deﬁcient mice are less susceptible to West Nile virus
infection as a result of an uncompromised blood-brain barrier (29). However, other
studies utilizing herpes simplex virus 1 as an infection model showed that TNFR1-
deﬁcient mice are more susceptible to virus infection (30, 31). It is clear that TNF-
deﬁcient mice exhibit CD169 cells in the spleen, whereas this cell population is absent
in Lt/mice (26, 27). Furthermore, the production of neutralizing antibodies and the
proliferation of antiviral T cells can be induced in TNF-deﬁcient animals (28, 32). These
ﬁndings suggest that TNF, which is crucial for overcoming bacterial infections (33–36),
plays a minor role in antiviral immunity.
In this study, we found that absence of TNF reduced the number of CD169 cells;
inhibited IFN-I production; and, consequently, led to a severe disease outcome during
infection with VSV. These effects were mainly transmitted by TNFR1 and were depen-
dent on canonical nuclear factor B (NF-B).
RESULTS
TNF production by CD11b Ly6C Ly6G cells following VSV infection. TNF can
be detected during an infection with VSV (32, 37). Consistently, we found that TNF
expression levels were higher in the spleen after infection with VSV than in uninfected
controls (Fig. 1A). Backgating of intracellular-TNF-producing cells showed that TNF-
producing cells are a heterogeneous CD11b CD19 population (Fig. 1B and C).
Therefore, we hypothesized that TNF was likely not expressed by B or T cells during
infection. Accordingly, we observed TNF mRNA expression levels in Cd8/, B-cell-
deﬁcient Jh/, and Rag1/ mice that were comparable to those in wild-type (WT)
mice (Fig. 1D). TNF-producing cells could be predominantly characterized as CD11b
CD11c Ly6C Ly6Gmajor histocompatibility complex class II negative (MHC-II) (Fig.
1E). Consistent with reports that neutrophils (38, 39) and CD11b Ly6C Ly6G cells
(40) are important during early defense against bacterial and viral infections via
production of proinﬂammatory cytokines, such as interleukin 1b (IL-1b), IL-6, TNF, and
IFN-I, we found a signiﬁcant increase of TNF CD11b Ly6C Ly6G cells (Fig. 1F).
Treatment with clodronate encapsulated in liposomes (clodronate liposomes) can
deplete phagocytic cells in mice (Fig. 1G) (41, 42). Accordingly, clodronate depletion
reduced TNF expression after VSV infection, suggesting a role of these phagocytic cells
in the production of TNF (Fig. 1H). However, when we employed diphtheria toxin
receptor (DTR)-induced speciﬁc depletion of CD169 cells and CD11c cells, we did not
observe a reduction in TNF production (Fig. 1H). Taken together, these ﬁndings indicate
that TNF production following intravenous VSV infection is triggered by CD11b
CD11c Ly6C Ly6G phagocytes.
TNF triggers the maintenance of CD169 cells during viral infection to protect
animals against the development of severe disease. To determine whether TNF
affects the outcome after VSV infection, we infected WT and TNF-deﬁcient mice.
TNF-deﬁcient mice developed severe VSV infection in comparison to WT mice (Fig. 2A).
A neutralizing antibody titer was achieved later in TNF-deﬁcient mice than in WT mice
after infection with low doses of VSV (Fig. 2B). Since IFN-I is critical to overcome an
infection with VSV (15), we measured IFN- and IFN- in the sera of infected animals.
IFN- production was impaired in TNF-deﬁcient mice compared to control animals (Fig.
2C). However, IFN- was undetectable in the sera of animals infected with 105 PFU VSV
(Fig. 2C). Previous ﬁndings showed that CD169 cells contribute to innate immune
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FIG 1 Vesicular stomatitis virus infection leads to inﬁltration of TNF-producing phagocytes. (A to F) WT mice were infected with 2  108 PFU VSV.
(A) TNF- mRNA expression levels in WT spleen tissue were determined at the indicated time points after infection (n  4 to 10). (B) Surface
molecule expression of CD11b, CD11c, CD8, and CD19 on TNF cells 4 h after infection (purple gate, whole spleen; pink gate, TNF cells; one
representative result out of 5 is shown). Numbers below the histograms indicate ﬂuorescence intensities. FSC, forward scatter; SSC, side scatter.
(C) Splenocytes from WT mice were stained for intracellular-TNF production. TNF CD11b cells were determined as percentages of total CD11b
cells (n  5). (D) TNF- mRNA expression in the spleens of WT, Jh/, Rag/, and CD8/ mice was determined 4 h after infection (n  5 or 6).
(E) Surface molecule expression of TNF-producing cells 4 h after infection. CD3 CD8 CD19 NK1.1 cells were further characterized for
(Continued on next page)
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activation in mice, not only by allowing viral replication, but also by producing IFN-I (10,
43). When we depleted CD169 cells expressing diphtheria toxin receptor (CD169-DTR
cells) by administering diphtheria toxin (DT) (44), we observed reduced IFN-I concen-
trations in the sera of infected animals (Fig. 2D). To exclude the possibility of defective
innate Toll-like receptor (TLR) activation, we administered the TLR3 agonist poly(I·C). We
found that the IFN-I production was intact in both WT and TNF-deﬁcient mice (Fig. 2E).
Hence, we speculated that TNF promoted the function of CD169 cells and thus
contributed to IFN-I production following VSV infection. Shortly after infection with
VSV, the number of CD169 cells in spleen tissue decreased in TNF-deﬁcient mice
compared to spleen tissue harvested from WT animals (Fig. 2F to H). To understand the
reduced production of IFN-I in the absence of TNF, we monitored the virus replication
in spleen tissue of WT and Tnfa/ mice. The expression of VSV glycoprotein (VSV-G)
was detected in smaller quantities in spleen tissue harvested from TNF-deﬁcient
animals than in spleen tissue harvested from WT mice after VSV infection (Fig. 2I and
J). Consistently, early VSV titers after infection were lower in Tnfa/ mice than in
control mice, a condition that negatively affected antiviral immune activation (Fig. 2K).
Injection of UV light (UV)-inactivated virus could increase TNF mRNA expression in WT
mice (Fig. 2L). However, the decrease of CD169 cells was dependent on live virus,
because UV-inactivated virus did not affect CD169 cells in spleen tissue of Tnfa/
mice (Fig. 2M). These ﬁndings indicate that TNF is necessary to sustain virus replication
in the early hours of infection but is dispensable for sterile innate immune activation.
Notably, CD169/ mice exhibited VSV-G expression in spleen tissue, a ﬁnding indi-
cating that downregulation of the protein CD169 would not cause absence of virus
replication (Fig. 2N). Taken together, these ﬁndings indicate that the absence of TNF
results in defective antiviral innate immune activation after infection with VSV.
CD169 cell maintenance via TNFR1 results in productive VSV replication and
immune activation. To further characterize the role of TNF during viral infection, we
infected TNFR1- and TNFR2-deﬁcient mice with VSV. In line with ﬁndings from TNF-
deﬁcient animals, the absence of TNFR1, but not that of TNFR2, resulted in a decrease
in the number of CD169 cells in spleen tissue (Fig. 3A and B). Furthermore, VSV-G
production was lower in Tnfrsf1a/ animals than in WT or Tnfrsf1b/ mice (Fig. 3A).
Consistently, VSV titers were reduced in spleen tissue shortly after infection in
Tnfrsf1a/ animals, in sharp contrast to the ﬁndings in WT and Tnfrsf1b/ mice (Fig.
3C). Interestingly, IFN-I production was defective in Tnfrsf1a/mice but was also lower
in Tnfrsf1b/ animals than in WT control mice (Fig. 3D). IFN-I is necessary for the
expression of antivirally active ISGs (1). Consistently, we found reduced expression of
ISGs in the CNS of Tnfrsf1a/ mice after infection with VSV (Fig. 3E). Defective ISG
expression was not found to the same extent in Tnfrsf1b/ CNS tissue (Fig. 3F). VSV
can drive neuropathological symptoms by infecting the CNS (22). When we measured
viral titers in the spinal cord and brain tissue of mice exhibiting hind leg paralysis, we
found infectious VSV in tissue from TNFR1-deﬁcient mice (Fig. 3G). Consequently,
Tnfrsf1a/ mice developed clinical signs of CNS infection, unlike WT and Tnfrsf1b/
mice (Fig. 3H). Taken together, these ﬁndings suggest that TNFR1 drives antiviral
defense by promoting CD169 cell survival.
TNFR1 triggers the survival of CD169 cells. Next, we opted to determine which
factors drive the maintenance of CD169 cells and enforced viral replication after viral
infection. B-cell-mediated Lt production is important for splenic CD169 cells. Hence,
we wondered whether the defects in the absence of TNF were triggered by B cells.
FIG 1 Legend (Continued)
expression of CD11b, CD11c, Ly6C, Ly6G, F4/80, MHC-II, and CD115 on TNF cells (n  6). The numbers in the boxes are percentages of the
population positive for TNF expression. (F) CD3 CD8 CD19 NK1.1 CD11b Ly6C Ly6G TNF cells were quantiﬁed in spleen tissue 4 h after
infection (n  6). (G) Mice were injected with liposomes containing phosphate-buffered saline (PBS; PBS liposomes) or clodronate liposomes, and
spleen tissue was harvested after 24 h. Sections of snap-frozen spleen tissue were stained with anti-F4/80 antibodies (n  3). (H) TNF- mRNA
expression was determined in the spleens of WT, clodronate-treated WT, Ifnar/, DT-treated CD169-DTR, and CD11c-DTR mice 4 h after infection
(n  6). ns, not signiﬁcant. The error bars indicate SEM.
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FIG 2 Tumor necrosis factor is required for early innate immune activation via maintenance of CD169 cells during viral infection. (A to D) Mice were infected
with 105 PFU VSV. (A) Survival of WT and TNF--null (Tnfa/) mice was monitored for 20 days after infection (n  9 to 12). (B) Titers of neutralizing total
immunoglobulin (Ig) (left) and IgG (right) were determined in WT and Tnfa/ mice at the indicated time points after infection (n  7). (C) IFN- and IFN-
concentrations were determined in the sera of WT and Tnfa/ mice 24 h after infection (n  6 to 9). (D) IFN- levels were determined in sera from WT and
CD169-DTR mice 24 h after infection (n  6). (E) IFN- and IFN- concentrations were determined in the sera of WT and Tnfa/ mice injected with 200 g
of poly(I·C) at the indicated time points (n  3). (F) WT and Tnfa/ mice were infected with 2  108 PFU of VSV. Snap-frozen spleen sections were stained
with anti-CD169 antibodies (clone MOMA-1) at the indicated time points (one representative result out of 6 mice is shown; scale bar  100 m). (G) The mean
ﬂuorescence intensity (MFI) of CD169 was quantiﬁed across spleen sections from naive and VSV-infected WT and Tnfa/ mice using ImageJ (1 to 3 images
(Continued on next page)
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Notably, we did not observe any major changes of B-cell subsets in TNF-, TNFR1-, or
TNFR2-deﬁcient mice (Fig. 4A). Consistently, we did not see differential expression of
Lt, Lt, or Lt receptor (LtbR) in TNFR1-deﬁcient mice (Fig. 4B). Additionally, we found
no major differences in B-cell subsets between WT and Tnfrsf1a/ mice after infection
(Fig. 4C). Furthermore, we reconstituted lethally irradiated C57BL/6 mice with mixed
bone marrow (BM) from Rag1/ and Tnfrsf1a/ and from Rag1/ and WT donors at
a ratio of 1:1. Mice reconstituted with Rag1/-Tnfrsf1a/ bone marrow exhibited no
signiﬁcant reduction in IFN- in the serum compared to mice reconstituted with
Rag1/-WT bone marrow (Fig. 4D). Furthermore, there was no difference between
these mice in neutralizing antibody production (Fig. 4E). To elucidate if TNFR1 deﬁ-
ciency speciﬁcally on CD169 cells has a role in virus replication, we reconstituted
lethally irradiated C57BL/6 mice with mixed bone marrow from CD169-DTR and
Tnfrsf1a/ donors, as well as CD169-DTR and WT donors, at a ratio of 1:1. We
observed that the production of IFN- was lower in the mice reconstituted with
CD169-DTR and Tnfrsf1a/ bone marrow compared to control mice reconstituted
with CD169-DTR and WT bone marrow after infection with VSV and DT treatment (Fig.
4F). Furthermore, we found slightly delayed presence of VSV neutralizing antibody
titers in CD169-DTR–Tnfrsf1a/ recipients compared to corresponding CD169-
DTR–WT recipients (Fig. 4G). CD169 cells can be depleted in CD11c-DTR mice,
because CD169 cells exhibit intermediate expression of CD11c (10, 45). Consistently,
lethally irradiated mice reconstituted with mixed bone marrow from CD11c-DTR and
Tnfrsf1a/ mice exhibited reduced concentrations of IFN- after VSV infection com-
pared to CD11c-DTR–WT bone marrow recipients (Fig. 4H). These ﬁndings suggest
that TNFR1 triggers cell-intrinsic effects on CD169 cells.
We speculated that TNF delivers an important survival signal for CD169 cells. To
determine if TNF is involved in protection against VSV-induced apoptosis, we measured
caspase 3 activity on whole spleen tissue lysates. After VSV infection, caspase 3 activity
was signiﬁcantly higher in Tnfa/ mice than in control animals (Fig. 5A). VSV is known
to induce apoptosis and inactivates Mcl-1 and Bcl-Xl (46). To elucidate if TNF plays a role in
promoting expression of antiapoptotic genes, we measured mRNA expression of Bcl2,
Bcl-Xl, and xIAP in spleen tissue of mice after VSV infection (Fig. 5B). After VSV infection, Bcl2
and Bcl-Xl expression was signiﬁcantly reduced in Tnfa/mice compared to WT mice (Fig.
5B). To enumerate the mechanism that reduces CD169 cells in TNF-deﬁcient mice after
infection, we made use of terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick
end labeling (TUNEL) assays. The number, as well as the mean ﬂuorescence intensity, of
TUNEL-positive CD169 cells was higher in spleen tissue from TNF-deﬁcient mice than in
tissue from corresponding WT control mice (Fig. 5C and D). The proportion of CD169 cells
that stained positive for 7-aminoactinomycin D (7-AAD) was higher in TNFR1-deﬁcient
mice than in WT control mice 8 h after infection (Fig. 5E). Next, we wondered if we could
rescue the CD169 cells by injecting the pancaspase inhibitor Z-Val-Ala-Asp-ﬂuoro-
methylketone (Z-VAD). Z-VAD treatment restored the presence of CD169 cells in TNF-
deﬁcient animals, a ﬁnding indicating that CD169 cells depend on TNF-mediated survival
(Fig. 5F and G). Although treatment of TNF-deﬁcient mice with Z-VAD-rescued CD169
cells, it failed to rescue the IFN-I response, suggesting the role of TNF signaling is essential
not only to prevent apoptosis, but also for IFN-I production (Fig. 5H). In summary, these
ﬁndings indicate that TNF delivers a survival signal that is important for the maintenance
of CD169 cells in the spleen after viral infection and for IFN-I production.
FIG 2 Legend (Continued)
per spleen from 3 or 4 mice were analyzed). (H) MFI from Tnfa/ mice normalized to WT MFI. (I) Snap-frozen spleen sections from WT and Tnfa/ mice were
stained for VSV-G expression (clone Vi10) after infection with 2  108 PFU VSV at the indicated time points (one representative result out of 6 mice is shown;
scale bar  100 m). (J) MFI of VSV-G expression quantiﬁed across spleen sections from naive and VSV-infected WT and Tnfa/ mice using ImageJ (1 to 3
images per spleen from 3 or 4 mice were analyzed). (K) WT and Tnfa/ mice were infected with 105 PFU VSV. Viral titers were measured in the spleens of WT
and Tnfa/ mice 8 h after infection with VSV (n  6). (L) Tnfa mRNA expression determined in spleen tissue of WT mice before and 4 h after injection with
UV-inactivated VSV (n  4). (M) Spleen tissue sections were stained with anti-CD169 antibodies in WT and Tnfa/ mice 8 h after infection with 2  108 PFU
of UV-inactivated VSV (one representative result out of 3 is shown). (N) Sections from snap-frozen spleen tissue harvested from WT and CD169/ mice were
stained for CD169 and VSV-G 7 h after infection with 2  108 PFU VSV (n  3; scale bar  100 m). The error bars indicate SEM.
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FIG 3 VSV replication is sustained via TNFR1 on CD169 cells. (A) Spleen tissue sections from WT, Tnfrsf1a/ (TNFR1), and Tnfrsf1b/ (TNFR2)
mice were stained with anti-CD169 and VSV-G antibodies 8 h after infection with 2  108 PFU of VSV (one representative result out of 6 mice
is shown; scale bar  100 m). (B) MFI of CD169 was quantiﬁed across spleen sections from WT, Tnfrsf1a/, and Tnfrsf1b/ infected mice, using
ImageJ (1 to 3 images per spleen from 3 or 4 mice were analyzed). (C to G) WT, Tnfrsf1a/, and Tnfrsf1b/ mice were infected with 105 PFU
(Continued on next page)
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The NF-B regulator MALT1 promotes canonical NF-B expression, VSV repli-
cation in CD169 cells, and immune activation during viral infection. TNF can
induce NF-B activation via TNFR1 and can promote the expression of genes driving
survival and of proinﬂammatory cytokines (47). Furthermore, TNF is known to promote
IFN-I production (48). Consistently, RelA expression was increased in the marginal zone
of spleen tissue after VSV infection (Fig. 6A). We quantiﬁed cytoplasmic and nuclear
expression of RelA in CD169 cells. The nuclear presence of RelA in CD169 cells was
higher in VSV-infected mice than in naive controls (Fig. 6B). We wondered whether
nuclear RelA protein expression was dependent on TNF. As expected, compared with
WT control mice, VSV-infected mice exhibited reduced expression of RelA in the nuclear
compartments of CD169 cells in the absence of TNF (Fig. 6C). Notably, the presence
of RelA was reduced in TNFR1-deﬁcient mice, but we observed no difference in RelA
expression between TNFR2-deﬁcient mice and corresponding control mice (Fig. 6D and
E). It has been reported that one of the major regulators of RelA signaling is RelB, which
acts through sequestration of RelA in the cytoplasm and competitive binding of DNA
(49). It has also been reported that the paracaspase MALT1 can promote canonical
NF-B signaling by cleaving RelB (50, 51). Hence, we stained spleen sections of
Malt1/ and Malt1/ mice for RelB. Ablation of MALT1 resulted in increased levels of
RelB in CD169 cells in the marginal zone of the spleen (Fig. 7A and B). In turn, nuclear
RelA levels were lower in CD169 cells in Malt1/ spleen tissue than in control tissue
(Fig. 7C). Consistently, mouse embryonic ﬁbroblasts (MEFs) derived from Malt1/mice
showed reduced translocation of p65 into the nucleus after stimulation with TNF but
higher expression of RelB in the nucleus (Fig. 7D and E). These ﬁndings indicate that
MALT1 destabilizes RelB in marginal-zone macrophages to promote canonical NF-B
signaling. The presence of CD169 cells in spleen tissue was not affected by Malt1
before or after infection with VSV (Fig. 8A). However, the expression of VSV-G was lower
in Malt1/ mice than in control mice (Fig. 8B and C). Consistently, the numbers of
infectious VSV particles were lower in spleen tissue harvested from Malt1/ mice than
in spleen tissue from control mice (Fig. 8D). Hence, serum IFN-I concentrations after VSV
infection were lower in MALT1-deﬁcient mice than in control mice (Fig. 8E). A previous
report suggested that MALT1 is not required for RIG-I activation (52). Consistently,
when we injected poly(I·C) into Malt1/ and Malt1/ mice, we found similar serum
IFN-I levels in both groups (Fig. 8F). Hence, we concluded that defective IFN-I produc-
tion during VSV infection was caused by reduced VSV replication early during infection.
Consequently, MALT1-deﬁcient mice succumbed to the infection, in sharp contrast to
control animals (Fig. 8G).
Taken together, these ﬁndings indicate that absence of MALT1 results in reduced
canonical NF-B signaling in response to VSV infection. Malt1-deﬁcient mice exhibit
reduced VSV replication and immune activation.
DISCUSSION
In this study, we found that TNF plays a crucial role in the maintenance of CD169
cells early after infection with VSV. Consequently, TNF-, TNFR1-, and MALT1-deﬁcient
animals exhibited reduced immune activation and limited IFN-I production, which
consequently led to severe VSV infection.
The role of TNF during viral infection is controversial and not sufﬁciently under-
FIG 3 Legend (Continued)
VSV. (C) Viral titers were measured in spleen tissue 8 h after infection in WT, Tnfrsf1a/, and Tnfrsf1b/ mice (n  6 to 9). The gap and dotted
lines represent the detection limit of the virus plaque assay. (D) IFN- concentrations were determined in the sera of WT, Tnfrsf1a/, and
Tnfrsf1b/ mice 24 h after infection with VSV (n  6 to 9). (E) WT and Tnfrsf1a/ mice were infected with 105 PFU VSV. RNA expression levels
of the indicated genes were determined in brains and spinal cords 24 h after infection (n  4 to 7). The highest relative expression values
(brain/spinal cord) were as follows: Eif2ak2, 13.72/7.98; Iﬁt2, 5.41/6.13; Iﬁt3, 35.99/34.15; Irf7, 68.80/54.55; Isg15, 42.54/51.23; Oasl1, 70.43/84.94. (F)
WT and Tnfrsf1b/ mice were infected with 105 PFU VSV. RNA expression levels of the indicated genes in brains and spinal cords were
determined 24 h after infection (n  3 or 4). The highest relative expression values (brain/spinal cord) were as follows: Eif2ak, 29.84/18.21; Iﬁt2,
7.99/10.24; Iﬁt3, 41.05/51.25; Irf7, 166.79/88.58; Isg15, 29.78/52.99; Oasl1, 75.60/114.39. (G) Viral titers were measured in brain and spinal cord tissue
of WT and Tnfrsf1a/ mice once Tnfrsf1a/ mice exhibited hind limb paralysis (n  3). (H) Survival of WT, Tnfrsf1a/, and Tnfrsf1b/ mice was
monitored over time after infection with VSV (n  15 to 24). The error bars indicate SEM.
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FIG 4 TNFR1 on CD169 cells is essential for early IFN-I response. (A) Follicular B cells (CD19 CD23) (FB), marginal-zone B
cells (CD19 CD21 CD23) (MZB), and regulatory B cells (CD19 CD21 CD5 IgM) (RB) were analyzed in naive WT and
Tnfa/-, Tnfrsf1a/-, and Tnfrsf1b/-deﬁcient mice (n  6). (B) Lymphotoxin  (Lt), Lt, and lymphotoxin  receptor (LtR)
gene expression was determined in spleen tissue from WT and Tnfrsf1a/ mice by RT-PCR (n  3). (C) Splenic B-cell
populations (FB, MZB, and RB) were analyzed after infection with 2  108 PFU of VSV in WT and Tnfrsf1a/ mice at the
indicated time points (n  5). (D) IFN- concentrations were determined 24 h after infection with 105 PFU VSV in the sera of
lethally irradiated mice reconstituted with either WT-Rag/ or Tnfrsf1a/-Rag/ bone marrow at a ratio of 1:1 (n  4). (E)
Neutralizing total immunoglobulin (left) and IgG (right) antibody titers were determined in the sera of WT-Rag/ or
Tnfrsf1a/-Rag/ reconstituted animals (n  4). (F to H) Lethally irradiated WT mice were reconstituted with BM from WT
or Tnfrsf1a/ mice mixed with BM from CD169-DTR (F) and CD11c-DTR (H) mice at a 1:1 ratio. After 40 days, the mice were
infected with 105 PFU of VSV. Before infection, the mice were treated with 2 doses of 100 ng DT via intraperitoneal injection.
(F) IFN- concentrations were determined 24 h after infection in the sera of WT–CD169-DTR and Tnfrsf1a/–CD169-DTR
reconstituted animals (n 4 or 5). (G) Neutralizing total immunoglobulin (left) and IgG (right) antibody titers were determined
in the sera of WT–CD169-DTR and Tnfrsf1a/–CD169-DTR reconstituted animals after infection with 105 PFU VSV at the
indicated time points (n 4). (H) IFN- concentrations were determined 24 h after infection in the sera of WT–CD11c-DTR and
Tnfrsf1a/–CD11c-DTR reconstituted mice (n  4 or 5). The error bars indicate SEM.
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FIG 5 Tumor necrosis factor mediates survival of CD169 cells via TNFR1. (A to E) Mice were infected with 2  108 PFU VSV. (A)
Caspase 3 activity was determined in spleen tissue harvested from WT and Tnfa/ mice 6 h after infection with 2  108 PFU VSV
(n  4 to 7). (B) Bcl2, Bclxl, and Xiap RNA expression was determined in spleen tissue from WT and Tnfrsf1a/ mice 8 h after infection
(n  3). (C) Tissue sections from WT and Tnfa/ mice were TUNEL stained 5 h after infection (one result representative of 3 or 4 mice
is shown; scale bar  10 m). (D) MFI of TUNEL quantiﬁed across spleen sections from naive and VSV-infected WT and Tnfa/ mice
using ImageJ (1 or 2 images per spleen from 3 or 4 mice were analyzed). (E) At the indicated time points, the proportions of 7AAD
cells among CD11b CD169 cells were determined (n  5) in WT and Tnfrsf1a/ mice. (F) WT, Tnfa/, and Tnfrsf1a/ mice were
treated with Z-VAD and infected with 2  108 PFU VSV. Spleen tissue sections were stained with anti-CD169 antibodies 8 h after
infection (one result representative of 3 or 4 mice is shown; scale bar  100 m). (G) MFI of CD169 quantiﬁed across spleen sections
from naive and VSV-infected WT and Tnfa/ mice treated with Z-VAD, using ImageJ (1 to 3 images per spleen from 3 or 4 mice were
analyzed). (H) IFN- concentrations determined 24 h after infection in the sera of Z-VAD-treated WT and Tnfa/ mice after infection
with 105 PFU of VSV (n  3). The error bars indicate SEM.
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stood. Although reports describe activating polymorphisms in TNF, which are associ-
ated with the establishment of a chronic viral infection (53), other reports state that the
same mutations are protective against chronic hepatitis B virus (HBV) infection (54). In
vitro, TNF can propagate the replication of hepatitis C virus (HCV) (55), although HCV
increases the incidence of TNF-induced apoptosis (56). On the other hand, TNF strongly
inhibits inﬂuenza virus replication in porcine lung epithelial cells (57). Consistently, the
attenuation of TNF signaling in a murine T-cell-independent model of HBV infection
FIG 6 VSV infection leads to TNFR1-dependent canonical NF-B activation in splenic CD169 cells. (A to D) Sections of snap-frozen spleen tissue were harvested
4 h after infection with 2  108 PFU VSV. (A) The sections were stained for RelA before and after infection (one representative result out of 3 is shown; scale
bar  100 m). Enlarged images of the boxed areas in the merged images on the left side are shown on the right (scale bar  5 m). (B) MFI of cytoplasmic
and respective nuclear RelA quantiﬁed in CD169 cells from WT mice before and after VSV infection to evaluate nuclear translocation of RelA (n  48 to 63).
(C to E) Spleen sections from WT and Tnfa/ (C), Tnfrsf1a/ (D), and Tnfrsf1b/ (E) mice were stained with anti-RelA antibodies 4 h after infection with
2  108 PFU VSV. The MFI of RelA in the nuclei of CD169 cells was determined with ImageJ software (n  35 to 57). The error bars indicate SEM.
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results in viral persistence (58). In turn, the application of second mitochondrion-
derived activator of caspases (SMAC) mimetics enhances TNF signaling and is associ-
ated with increased clearance of HBV in this model system (59). During infection with
VSV, the production of neutralizing antibodies is not defective in the absence of TNFR1
(32). Moreover, TNF can induce T-cell dysfunction and therefore promote chronic viral
FIG 7 MALT1 regulates nuclear RelA expression after infection with vesicular stomatitis virus. (A) Sections from snap-frozen spleen tissue harvested from naive
Malt1/ and Malt1/ mice were stained with anti-RelB antibodies (one representative result out of 3 is shown; scale bar  10 m). (B) MFI of cytoplasmic
and nuclear RelB was quantiﬁed in CD169 cells using ImageJ (n  39 to 42). (C) Sections of snap-frozen spleen tissue from Malt1/ and Malt1/ mice were
stained with anti-RelA antibodies 4 h after infection with 2  108 PFU VSV. The MFI in the nuclei of CD169 cells was quantiﬁed (n  29 to 41). (D and E)
Malt1/ and Malt1/MEFs were stimulated with 100 ng/ml recombinant mouse tumor necrosis factor (rmTNF) at the indicated time points. Cytosolic extracts
(CE) and nuclear extracts (NE) were harvested and probed for p65. Densitometry analysis of p65 and RelB was performed on the Western blot (WB) images from
cytosolic and nuclear fractions at the indicated time points. Proteins were normalized to GAPDH or histone (n  4). The error bars indicate SEM.
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infection (60). Our ﬁnding that TNF is crucial for the maintenance of CD169 cells in
spleen tissue may be important for infections with lower doses of virus, because
allowing viral replication in CD169 cells is particularly important for protective adap-
tive immunity (9, 13). This may be crucial for the maintenance of CD169 cells in spleen
tissue during vaccination with attenuated virus strains or VSV vector-based vaccines
(25). These ﬁndings may not be speciﬁc only for splenic CD169 cells, since intranasal
infection with recombinant TNF overexpressing rabies virus (RV) reduced the RV load
and mortality (61).
Viral replication in CD169 cells, which is promoted by TNF, contributes to improved
antigen presentation. CD169 cells in the marginal zone are in close contact with
FIG 8 MALT1 promotes vesicular stomatitis virus replication in CD169 cells and immune activation during
viral infection. (A) Spleen sections from naive Malt1/ and Malt1/ mice were stained with anti-CD169
(one representative result out of 3 is shown; scale bar  100 m). (B) Sections of snap-frozen spleen tissue
from Malt1/ and Malt1/ mice were analyzed 8 h after infection with 2  108 PFU VSV and stained with
anti-CD169 and anti-VSV-G) (one representative result out of 3 is shown; scale bar  100 m). (C) MFI of
CD169 and VSV-G was quantiﬁed across spleen sections from VSV-infected Malt1/ and Malt1/ mice
using ImageJ (n  4). (D and E) Mice were infected with 105 PFU VSV. (D) Viral titers were measured in
spleen tissue of Malt1/ and Malt1/ mice 8 h after infection (n  6). (E) IFN- concentrations were
determined in the sera of Malt1/ and Malt1/ mice 24 h after infection (n  6). (F) IFN- concentrations
were determined in the sera of Malt1/ and Malt1/ mice injected with 200 g poly(I·C) at the indicated
time points (n  3 or 4). (G) Survival of Malt1/ and Malt1/ animals was monitored for 20 days after
infection (n  13 to 14). The error bars indicate SEM.
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pathogens and are ideally situated to induce an immune response (62). Furthermore,
CD169 cells have been shown not only to present antigens to B cells in the lymph
nodes, but also to prime T cells (11, 63). Moreover, CD169 cells are important for
virus-mediated IFN-I production, which prevents severe CNS infection in mice (64). Our
ﬁndings show that TNF promotes maintenance of CD169 cells and IFN-I production
following VSV infection. Furthermore, our ﬁndings show that the translocation of RelA
to the nuclei of CD169 cells after VSV infection is dependent on TNF. It has been
postulated that canonical NF-B can contribute to the production of IFN- (65, 66).
However, RelA-deﬁcient and p50-deﬁcient MEFs can produce IFN- after viral infection,
whereas only early IFN-I transcription is reduced (67, 68). Furthermore, RelA-deﬁcient
plasmacytoid dendritic cells (pDCs) exhibited reduced IFN production after exposure to
Sendai virus (69). Our ﬁndings indicate that canonical NF-B activation can also
promote early viral replication and consequently contribute to the production of IFN-I.
Consistently, noncanonical NF-B, which can inhibit canonical NF-B signaling, is a
potent inhibitor of IFN-I production (70). Hence, the paracaspase MALT1, which can
cleave RelB and consequently promote canonical NF-B signaling (50, 51), is necessary
for the sufﬁcient propagation of VSV replication and IFN-I production.
Taken together, we have found that TNF-TNFR1 signaling is crucial for protecting
CD169 cells and their function in innate immune activation during VSV infection.
MATERIALS AND METHODS
Mice, viruses, and virus titration. Tnfa/, Tnfrsf1b/, CD8/, and Rag1/ mice were purchased
from Jackson Laboratories (United States). Tnfrsf1a/ mice have been previously described (34).
Malt1/, CD169/, CD169-DTR, and CD11c-DTR mice have also been previously described (71–74). All
the mice were maintained on a C57BL/6 genetic background. VSV Indiana serotype (Mudd-Summers
strain) was originally obtained from D. Kolakofsky (University of Geneva, Geneva, Switzerland). VSV was
propagated and titrated as previously described (13). Mice were infected with VSV via tail vein injection.
In survival experiments, mice exhibiting symptoms of hind leg paralysis were considered “severe,” taken
out of the experiment, and counted as dead. Blood was collected at the indicated time points after
infection. VSV neutralizing antibody titers were measured by plaque reduction neutralization test
(PRNT) as previously described (9, 13). Brieﬂy, serum samples were diluted 1:40 and incubated at
56°C for 30 min. To evaluate immunoglobulin G (IgG), the serum was pretreated with 0.1 M
-mercaptoethanol. Serial 2-fold dilutions were performed for 12 steps, and the serum was incubated
with 5,000 PFU of VSV. The virus and serum mixture was incubated on a Vero cell monolayer. The plates
were stained with crystal violet after 24 h. To inhibit caspase activity in vivo, we administered three doses
(2 g/g of body weight each) of Z-VAD (Abcam, Cambridge, United Kingdom) (75, 76). For chimera
experiments, mice were lethally irradiated with 10.2 Gy. After 24 h, mixed bone marrow from WT or
Tnfrsf1a/ and CD169-DTR, CD11c-DTR, and Rag1/ mice was transplanted into the irradiated mice as
indicated. All mice were maintained under speciﬁc-pathogen-free conditions under the authorization of
the Landesamt für Natur, Umwelt und Verbraucherschutz of North Rhine-Westphalia (LANUV NRW) in
accordance with the German laws for animal protection.
Depletion of cells. To deplete macrophages, 200 l clodronate liposomes was injected intrave-
nously, and 24 h later, the mice were infected with VSV. Liposomes containing phosphate-buffered saline
(PBS; PBS liposomes) were used as a control. Clodronate and PBS liposomes were provided by Nico van
Rooijen (Vrije University Medical Center, Netherlands) and used as previously described (41, 42). CD169-
and CD11c-expressing cells in CD169-DTR and CD11c-DTR mice were depleted by injecting 2 doses of
100 ng DT (Sigma) 1 day before and on the day of infection.
Histology and ELISA. Histological analysis of snap-frozen tissue was performed as previously
described (9). Brieﬂy, snap-frozen tissue sections were cut at 7-m thickness, air dried, and ﬁxed with
acetone for 10 min. The sections were blocked with 2% fetal calf serum in phosphate-buffered saline
(PBS) for 1 h and stained with anti-CD169 (ﬁnal concentration, 4 g/ml; Acris, Germany; clone MOMA-1),
anti-VSV-G (ﬁnal concentration, 1 g/ml; produced in house; clone Vi10), anti-RelA (ﬁnal concentration,
1 g/ml; Santa Cruz Biotechnology, USA), anti-F4/80 (ﬁnal concentration, 2 g/ml; eBioscience; clone
BM8), and anti-RelB (ﬁnal concentration, 1 g/ml; Cell Signaling, USA; polyclonal) for 1 h. Then, the
sections were washed with PBS containing 0.05% Tween 20 (Sigma). The secondary antibodies, phyco-
erythrin (PE) streptavidin (ﬁnal concentration, 1 g/ml; eBioscience), anti-rabbit ﬂuorescein isothiocya-
nate (FITC) (ﬁnal concentration, 1 g/ml; Thermo Fisher), and anti-goat FITC (ﬁnal concentration, 1 g/ml;
Santa Cruz Biotechnology, USA), were incubated for 1 h. Then, the sections were washed with PBS
containing 0.05% Tween 20 (Sigma) and mounted using ﬂuorescence mounting medium (Dako). A
caspase 3 activity assay was performed with a ﬂuorescence assay (Cell Signaling) according to the
manufacturer’s instructions. TUNEL staining was performed on formalin-ﬁxed spleen sections according
to the manufacturer’s instructions (Thermo Scientiﬁc, USA). Images were obtained with an LSM510
confocal microscope and an Axio Observer Z1 ﬂuorescence microscope (Zeiss, Germany). Analysis of the
ﬂuorescence images was performed with ImageJ software. IFN- and IFN- (PBL Biosciences, New Jersey,
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USA) concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) according
to the manufacturers’ instructions.
Reverse transcription (RT)-PCR analyses. RNA puriﬁcation (Qiagen RNeasy kit or TRIzol) was
performed according to the manufacturer’s instructions. Gene expression of Bcl2, Bcl-xl, Xiap, Lta, Ltb, Iﬁt1,
Iﬁt2, Iﬁt3, Irf7, Isg15, Oasl1, and Tnfa was performed using 6-carboxyﬂuorescein (FAM) and VIC probes
(Applied Biosystems) and an iTAQ one-step PCR kit (Bio-Rad). For analysis, the expression levels of all the
target genes were normalized to -actin/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expres-
sion (ΔCT). Gene expression values were then calculated based on the ΔΔCT method, using naive WT mice
as a control to which all other samples were compared. Relative quantities (RQ) were determined using
the following equation: RQ  2ΔΔCT.
Immunoblotting. Malt1/ and Malt1/ MEFs were obtained from Jürgen Ruland (Technische
Universität Munich, Munich, Germany). Malt1/ and Malt1/ MEFs were stimulated with 100 ng/ml
murine soluble TNF (mTNF) (R&D Systems). Cytoplasmic and nuclear extracts were prepared using a
nuclear protein extraction kit according to the manufacturer’s instructions (Active Motif, Belgium).
Immunoblots were probed with primary anti-p65 (Santa Cruz Biotechnology), anti-RelB (Cell Signaling),
and anti-p100/p52 (Cell Signaling).
Flow cytometry. For intracellular-cytokine staining, single-cell suspended splenocytes were incu-
bated with brefeldin A (eBioscience), followed by an additional 5 h of incubation at 37°C. After surface
staining with anti-CD3, anti-CD8, anti-CD11b, anti-CD11c, anti-CD19, anti-CD115, anti-F4/80, anti-Ly6C,
anti-Ly6G, anti-MHC-II, and anti-NK1.1 antibodies (all from eBioscience), the cells were ﬁxed with 2%
formalin, permeabilized with 0.1% saponin, and stained with anti-TNF antibodies (eBioscience) for 30 min
at 4°C. B-cell subsets were detected in single-cell suspensions of splenocytes with anti-CD5, anti-CD19,
anti-CD21, anti-CD23, and anti-IgM antibodies (all from eBioscience). BD Calibrite (BD Biosciences, USA)
beads were added to the samples before acquisition with a BD LSRFortessa.
Statistical analyses. Data are represented with standard errors of the mean (SEM). Statistically
signiﬁcant differences between two groups were determined with Student’s t test. Statistically signiﬁcant
differences between several groups were determined by one-way analysis of variance (ANOVA) with
additional Bonferroni or Dunnett post hoc tests. Statistically signiﬁcant differences between groups in
experiments involving more than one time point were determined with two-way ANOVA (repeated
measurements).
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